The Australian Clinical Trials Alliance (ACTA) and the Australian Commission on Safety and Equality in Health Care have published a landmark report outlining the economic benefits of investigator-initiated clinical trials.
The report finds that, if the results of 25 high-impact clinical trials were implemented in 65% of the eligible Australian patient populations:
Benefits would exceed costs if the results of these trials were implemented in only 11% of the eligible patient populations.
For every $1 awarded in National Health and Medical Research Council (NHMRC) grants to the 25 trials, a return of $51.10 was achieved.
Just 9% of the $2 billion gross benefit from these trials equals NHMRC funding received by all Australian trial investigator networks between 2004 and 2014.
Download a copy of the full report here.